Natixis Advisors L.P. lifted its holdings in Seagen Inc. (NASDAQ:SGEN – Free Report) by 23.0% in the first quarter, according to the company in its most recent filing with the SEC. The fund owned 29,601 shares of the biotechnology company’s stock after acquiring an additional 5,535 shares during the quarter. Natixis Advisors L.P.’s holdings in Seagen were worth $5,993,000 at the end of the most recent quarter.
A number of other hedge funds have also recently made changes to their positions in SGEN. OLD Mission Capital LLC bought a new stake in shares of Seagen in the 4th quarter worth approximately $28,000. Corrado Advisors LLC bought a new stake in Seagen during the 4th quarter valued at $32,000. Achmea Investment Management B.V. bought a new stake in Seagen during the 1st quarter valued at $33,000. Parallel Advisors LLC raised its holdings in Seagen by 61.6% during the 1st quarter. Parallel Advisors LLC now owns 181 shares of the biotechnology company’s stock valued at $37,000 after buying an additional 69 shares during the last quarter. Finally, True Wealth Design LLC bought a new stake in Seagen during the 4th quarter valued at $39,000. 84.26% of the stock is currently owned by institutional investors.
Insider Activity at Seagen
In other news, insider Vaughn B. Himes sold 371 shares of the firm’s stock in a transaction dated Tuesday, August 29th. The shares were sold at an average price of $206.00, for a total transaction of $76,426.00. Following the sale, the insider now owns 53,234 shares of the company’s stock, valued at approximately $10,966,204. The sale was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. In other news, EVP Charles R. Romp sold 708 shares of the firm’s stock in a transaction on Monday, July 3rd. The stock was sold at an average price of $192.46, for a total value of $136,261.68. Following the transaction, the executive vice president now directly owns 59,069 shares in the company, valued at approximately $11,368,419.74. The transaction was disclosed in a document filed with the SEC, which is accessible through this link. Also, insider Vaughn B. Himes sold 371 shares of the company’s stock in a transaction on Tuesday, August 29th. The shares were sold at an average price of $206.00, for a total value of $76,426.00. Following the sale, the insider now owns 53,234 shares of the company’s stock, valued at approximately $10,966,204. The disclosure for this sale can be found here. In the last ninety days, insiders have sold 22,548 shares of company stock valued at $4,471,849. 25.90% of the stock is owned by insiders.
Analyst Upgrades and Downgrades
Read Our Latest Stock Report on Seagen
Seagen Stock Performance
Shares of SGEN stock opened at $206.85 on Thursday. Seagen Inc. has a one year low of $116.08 and a one year high of $209.39. The company’s 50-day moving average is $195.25 and its 200 day moving average is $193.25. The company has a market capitalization of $38.83 billion, a price-to-earnings ratio of -53.17 and a beta of 0.50.
Seagen (NASDAQ:SGEN – Get Free Report) last announced its quarterly earnings data on Wednesday, August 2nd. The biotechnology company reported ($1.13) EPS for the quarter, missing the consensus estimate of ($0.78) by ($0.35). Seagen had a negative net margin of 33.54% and a negative return on equity of 26.46%. The firm had revenue of $603.83 million for the quarter, compared to analysts’ expectations of $555.68 million. As a group, research analysts predict that Seagen Inc. will post -3.4 earnings per share for the current fiscal year.
Seagen Profile
Seagen Inc, a biotechnology company, develops and commercializes therapies for the treatment of cancer in the United States and internationally. It offers ADCETRIS, an antibody-drug conjugate (ADC) for the treatment of patients with Hodgkin lymphoma or CD30-positive T-cell lymphomas; PADCEV, an ADC targeting Nectin-4 for the treatment of adult patients with advanced or metastatic urothelial cancer; and TUKYSA, an oral small molecule tyrosine kinase inhibitor for the treatment of adult patients with advanced unresectable or metastatic HER2-positive breast cancer.
See Also
- Five stocks we like better than Seagen
- Profitably Trade Stocks at 52-Week Highs
- Why Ambarella’s 20% Decline is a Strong Signal for New Investment
- EV Stocks and How to Profit from Them
- Why Analysts Love These 2 Car Sales Platforms, And Avoid Dealers
- Large Cap Stock Definition and How to Invest
- A Significant Reversal is in Sight for These 5 Med Tech Companies
Receive News & Ratings for Seagen Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Seagen and related companies with MarketBeat.com's FREE daily email newsletter.
